ArriVent BioPharma, Inc. (NASDAQ: AVBP) was upgraded by analysts at B. Riley to a "strong-buy" rating.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at B. Riley. They set a "buy" rating and a $37.00 price target on the stock.
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts [Yahoo! Finance]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.